Chronic Hepatitis B.

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis B virus (HBV) infection requires effective antiviral therapies.
• Current treatment options include interferon alpha, lamivudine, and adefovir, each with distinct efficacy and limitations.
• Individualized treatment strategies are essential for optimizing patient outcomes in chronic HBV management.

Purpose of the Study:

• To review the current therapeutic landscape for chronic hepatitis B.
• To compare the efficacy, limitations, and side effect profiles of interferon alpha, lamivudine, and adefovir.
• To discuss considerations for individualized therapy and future treatment directions.

Main Methods:

• Literature review of approved antiviral agents for chronic HBV.
• Comparative analysis of clinical trial data for interferon alpha, lamivudine, and adefovir.
• Discussion of patient selection criteria and treatment individualization.

Main Results:

• Interferon alpha offers HBsAg loss in 30-40% but has side effects and parenteral administration limitations.
• Lamivudine shows high HBV DNA suppression and histologic improvement but is limited by significant drug resistance (up to 55% at 3 years).
• Adefovir demonstrates efficacy against wild-type and lamivudine-resistant HBV with low resistance risk (2-3% at 2 years).

Conclusions:

• Therapy selection for chronic HBV should be individualized based on patient comorbidities, prior response, and disease stage.
• Emerging therapies and combination treatments hold promise for enhanced efficacy and reduced drug resistance in the future.
• Concurrent consideration of liver transplantation is vital for patients with decompensated liver disease.